CClinicalTrials.gg
Not yet recruitingNCT07066683FatMobCMT1AUpdated Feb 19, 2026

Pilot Study to Evaluate Fatigue and Fatigability Profiles and Their Impact on Walking and Balance in Patients With Charcot-Marie-Tooth Type 1A Disease Using a Global Approach in Comparison to Healthy Volunteers

An interventional study of CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION) and ACTIVITIES AND PARTICIPATION in Charcot-Marie-Tooth Type 1A, sponsored by University Hospital, Strasbourg, France. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Feb 2026, 7 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years to 74 Years
Sex
All
01

Study summary

Charcot-Marie-Tooth disease type 1A is the most common form of inherited neuropathy that causes peripheral nerve damage in all four limbs. In addition to the well-known distal motor and sensory symptoms, fatigue is one of the most common symptoms reported by patients. However, there is very little scientific data on this topic. Fatigue is associated with changes in mobility and quality of life. This study investigates the magnitude and impact of fatigue on patients' sensory-motor function and mobility (standing and walking). Fatigue is a complex phenomenon. It is therefore essential to assess all the factors that may be at the origin of this symptom (perceived fatigue and fatigability) using innovative and robust assessment methods.

These methods are based on quantitative non-invasive neurophysiologic measures (electromyography and transcranial magnetic stimulation). The patients can quantify and identify more precisely the origin of fatigability (peripheral and central). This objective approach needs to be combined with the usual methods of measuring fatigue using valid and reliable patient-reported outcome measures. A quantitative measure of movement during walking must also be included to assess changes in fatigue during functional movement.

To quantify the proportion of fatigue associated with CMT1A, the investigators chose to compare data from patients with those of healthy subjects matched for age, height and lean body mass.

A better understanding of the role of fatigue in limiting walking and balance capacities in these patients will allow the investigators to refine the inpatient and outpatient management.

02

Conditions studied

  • Charcot-Marie-Tooth Type 1A
03

In context

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria for patients:

  • Age ≥ 18 years and \< 75 years
  • Patient with mCMT1A confirmed by genetic analysis (based on data recorded in the patient file)
  • Patient able to walk a minimum of 200 metres without a break, with or without equipment and/or technical aids (collected during questioning)
  • Patient able to get on and off a cycloergometer safely without assistance or with minimal assistance
  • Patient who has had a cardiological check-up before the stress test (ECG and cardiac ultrasound less than 6 months old) or for whom a check-up is scheduled before the inclusion
  • Patient affiliated to a health insurance scheme or beneficiary of such a scheme

Inclusion criteria for Healthy volunteers:

  • Age ≥ 18 years and \< 75 years
  • Subject affiliated to or benefiting from a health insurance scheme
  • Subject who has had a cardiological work-up prior to stress testing (ECG and cardiac ultrasound less than 6 months old) or for whom a work-up is scheduled prior to the procedure.

Exclusion criteria for patients:

  • Patients with all other forms of neuropathy (HNPP, other types of CMT, secondary neuropathies)
  • Patients with any of the following

    • An associated neurological disease other than mCMT1A
    • Severe joint disease of the lower limbs
    • Contraindication to isokinetic testing
    • Contraindication to an exercise stress test and exercise reconditioning program
    • A contraindication to Transcranial Magnetic Stimulation (TMS) : epilepsy, intracranial metallic foreign body, hearing aid or cochlear implant, unstable skull bone fracture, deafness, etc.
  • Patients who have undergone lower limb surgery in the 12 months prior to inclusion or for whom lower limb surgery is scheduled during the participation period.
  • Pregnant or breastfeeding or planning to become pregnant within the next 4 months
  • BMI > 35 kg/m2
  • Patient unable to give informed consent, unable to understand informed information
  • Subject under court protection
  • Subject under guardianship or curatorship
  • Subject in a period of exclusion (determined by a previous or current study)

Exclusion criteria for healthy volunteers:

  • History of neurological disease
  • Severe joint damage in the lower limbs
  • Any of the following

    • Contraindication to isokinetic testing
    • A contraindication to an exercise stress test and an exercise reconditioning program
    • A contraindication to TMS: epilepsy, intracranial metallic foreign body, hearing aid or cochlear implant, unstable skull bone fracture, deafness, etc.
  • Any person who has undergone surgery on the lower limbs in the 12 months prior to inclusion, or for whom surgery on the lower limbs is scheduled during the participation period.
  • Pregnant or breastfeeding, or planning to become pregnant within the next 4 months
  • Person unable to give informed consent, unable to understand informed information
  • BMI > 35 kg/m2
  • Person under legal protection
  • Person under guardianship or curatorship
  • Person in a period of exclusion (determined by a previous or current study)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Charcot Marie Tooth type 1A

    CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION): * Perceived fatigue * Mental functions * Sensory functions and pain * Neuromusculoskeletal and movement-related functions * Functions of the cardiovascular and respiratory systems o Exercise stress test * Fatigability (neuromuscular fatigue) * Lower limbs * Maximum voluntary strength * Study of the central and peripheral components of fatigue ACTIVITIES AND PARTICIPATION * Mobility * Clinical standard tests for balance and walking * Quantified motion analysis * Activity level * Quality of life

    Other: CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION) and ACTIVITIES AND PARTICIPATION

  • Active comparator
    Healthy subjects matched for age, height and lean body mass.

    Identical to patient, except for Charcot-Marie-Tooth specific tests

    Other: CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION) and ACTIVITIES AND PARTICIPATION

Interventions

  • OtherCLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION) and ACTIVITIES AND PARTICIPATION

    Tip: Ensure that this name matches the name used in the associated Arm Description. CLINICAL ASSESSMENT OF BODY FUNCTION (PROM AND PHYSICAL EXAMINATION): * Perceived fatigue * Mental functions * Sensory functions and pain * Neuromusculoskeletal and movement-related functions * Functions of the cardiovascular and respiratory systems o Exercise stress test * Fatigability (neuromuscular fatigue) * Lower limbs * Maximum voluntary strength and power * Study of the central and peripheral components of fatigue ACTIVITIES AND PARTICIPATION * Mobility * Clinical standard tests for balance and walking * Quantified motion analysis * Activity level Quality of life The same evaluation tests will be performed on patients and healthy volunteer controls

06

What researchers measure

Primary outcomes

  1. Fatigability profile

    Difference in isometric force developed by the knee extensors (assessment of overall neuromuscular fatigue) before and after a tiring exercise (stress test), during a maximum voluntary contraction, expressed in N.m-1, assessed on an isokinetic dynamometer (CONTREX®), compared between patients with mCMT1A and healthy volunteers.

    Time frame: 7 days

07

Study locations

1 site
  • Pôle de médecine physique et de réadaptation, Hôpital de Hautepierre, Strasbourg Centre de référence des maladies neuromusculaires, Institut Universitaire de Réadaptation Clémenceau, Strasbourg
    Strasbourg, 67000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07066683
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Jul 15, 2025
Start date
Feb 20, 2026 (estimated)
Primary completion
Feb 20, 2026 (estimated)
Completion
Feb 2028 (estimated)
Last update
Feb 19, 2026

Study contacts

Charles PRADEAU
Contact
charles.pradeau@chru-strasbourg.fr
03.88.21.16.28

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion